1.Current role of multiparametric magnetic resonance imaging in the management of prostate cancer.
Nikolas Christopher KATELARIS ; Damien Michael BOLTON ; Mahesha WEERAKOON ; Liam TONER ; Phillip Mark KATELARIS ; Nathan LAWRENTSCHUK
Korean Journal of Urology 2015;56(5):337-345
The purpose of this review was to evaluate the current role of multiparametric magnetic resonance imaging (mp-MRI) in the management of prostate cancer (PC). The diagnosis of PC remains controversial owing to overdetection of indolent disease, which leads to overtreatment and subsequent patient harm. mp-MRI has the potential to equilibrate the imbalance between detection and treatment. The limitation of the data for analysis with this new technology is problematic, however. This issue has been compounded by a paradigm shift in clinical practice aimed at utilizing this modality, which has been rolled out in an ad hoc fashion often with commercial motivation. Despite a growing body of literature, pertinent clinical questions remain. For example, can mp-MRI be calibrated to reliably detect biologically significant disease? As with any new technology, objective evaluation of the clinical applications of mp-MRI is essential. The focus of this review was on the evaluation of mp-MRI of the prostate with respect to clinical utility.
*Disease Management
;
Humans
;
Magnetic Resonance Imaging/*methods
;
Male
;
Prostate/*pathology
;
Prostate-Specific Antigen/blood
;
Prostatectomy
;
Prostatic Neoplasms/*diagnosis/pathology/surgery
2.Clinical Use of -2proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature.
Alberto ABRATE ; Giovanni LUGHEZZANI ; Giulio Maria GADDA ; Giuliana LISTA ; Ella KINZIKEEVA ; Nicola FOSSATI ; Alessandro LARCHER ; Paolo DELL'OGLIO ; Francesco MISTRETTA ; Nicolomaria BUFFI ; Giorgio GUAZZONI ; Massimo LAZZERI
Korean Journal of Urology 2014;55(7):436-445
Prostate-specific antigen (PSA) is recognized as an organ-specific marker with low specificity and sensitivity in discriminating prostate cancer (PCa) from other benign conditions, such as prostatic hyperplasia or chronic prostatitis. Thus, in the case of clinical suspicion, a PCa diagnosis cannot be made without a prostate biopsy. [-2]proPSA (p2PSA), a precursor of PSA, has been investigated as a new marker to accurately detect PCa. The aim of this systematic review was to discuss the available literature regarding the clinical validity and utility of p2PSA and its derivatives, p2PSA/fPSA (%p2PSA) and the Prostate Health Index (PHI). A systematic search of the PubMed and Scopus electronic databases was performed in accordance with the PRISMA statement (http://www.prisma-statement.org), considering the time period from January 1990 to January 2014 and using the following search terms: proprostate specific antigen, proenzyme PSA, proPSA, [-2]proPSA, p2PSA, Prostate Health Index, and PHI. To date, 115 studies have been published, but only 35 were considered for the qualitative analysis. These studies suggested that p2PSA is the most cancer-specific form of PSA, being preferentially expressed in PCa tissue and being significantly elevated in the serum of men with PCa. It is now evident that p2PSA, %p2PSA, and PHI measurements improve the specificity of the available tests (PSA and derivatives) in detecting PCa. Moreover, increasing PHI values seem to correlate with more aggressive disease. Some studies have compared p2PSA and its derivatives with other new biomarkers and found p2PSA to be significantly more accurate. Indeed, the implementation of these tests in clinical practice has the potential to significantly increase the physician's ability to detect PCa and avoid unnecessary biopsies, while also having an effective impact on costs. Further studies in large, multicenter, prospective trials are required to confirm these encouraging results on the clinical utility of these new biomarkers.
Humans
;
Male
;
Prostate-Specific Antigen/*blood
;
Prostatectomy
;
Prostatic Neoplasms/*diagnosis/pathology/surgery
;
Protein Isoforms/blood
;
Protein Precursors/*blood
;
Sensitivity and Specificity
;
Severity of Illness Index
;
Tumor Markers, Biological/blood
3.Can We Predict Real T3 Stage Prostate Cancer in Patients with Clinical T3 (cT3) Disease before Radical Prostatectomy?.
Hye Won LEE ; Seong Il SEO ; Seong Soo JEON ; Hyun Moo LEE ; Han Yong CHOI
Yonsei Medical Journal 2010;51(5):700-707
PURPOSE: Down-staging of clinical T3 (cT3) prostate cancer after radical prostatectomy (RP) is not uncommon due to the inaccuracy of the currently available staging modalities, although selected down-staged cT3 patients can be a candidate for definitive RP. We identified the significant predictors for down-staging of cT3 after RP. MATERIALS AND METHODS: We included 67 patients with cT3 stage prostate cancer treated with radical perineal prostatectomy (RPP) between 1998 and 2006 and reviewed their medical records retrospectively. The clinical stage was obtained according to the DRE, the prostate biopsy findings, and the prostate MRI. RESULTS: Fifty three (79%) patients with cT3 prostate cancer were down-staged to pT2 after RP. The percent of positive cores had the strongest association with down-staging of cT3 [p = 0.01, odds ratio (OR) = 6.3], followed by baseline prostate specific antigen (PSA) (p = 0.03, OR = 5.0), the biopsy Gleason sum (GS) (p = 0.03, OR = 4.7), and the maximum tumor volume of the positive cores (p = 0.05, OR = 4.0). When the cut-off points of significant parameters which were a PSA < 10 ng/mL, a percent of positive cores < or = 30%, a maximum tumor volume of the positive cores < or = 75% and GS < or = 7 were combined, the sensitivity, specificity, and positive predictive value were 0.25%, 1.00%, and 100%, respectively. CONCLUSION: The percent of positive cores < or = 30%, serum PSA < 10 ng/mL, the biopsy GS < or = 7, and the maximum tumor volume of the positive cores < or = 75% were the significant predictors of down-staging cT3 disease after RP.
Aged
;
Humans
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Predictive Value of Tests
;
Prostate-Specific Antigen/blood
;
*Prostatectomy
;
Prostatic Neoplasms/blood/diagnosis/*pathology/*surgery
4.Clinical outcomes of laparoscopic radical prostatectomy for high risk prostate cancer.
Pengfei SHAO ; Changjun YIN ; Email: CHANGJUNYIN@HOTMAIL.COM. ; Jie LI ; Pu LI ; Xiaobing JU ; Qiang LYU ; Xiaoxin MENG ; Lixin HUA
Chinese Journal of Surgery 2015;53(11):847-851
OBJECTIVETo study the technique and clinical outcomes of laparoscopic radical prostatectomy for high risk prostate cancer.
METHODSA total of 65 patients with high risk prostate cancer were treated with surgery in the First Affiliated Hospital of Nanjing Medical University from January 2011 to June 2013. The mean age was 67 years (range 45-75 years). The mean preoperative prostate specific antigen (PSA) level was 26.7 µg/L (range 11.2-65.5 µg/L). The transrectal biopsy revealed Gleason score of 3+3 in 4 patients, Gleason 3+4 in 27 patients, Gleason 4+3 in 11 patients, Gleason 4+4 in 21 patients and Gleason 4+5 in 2 patients. The bone metastasis was excluded by scintigraphy examination. The surgical procedures were performed through transperitoneal approach. Extended pelvic lymph nodes dissection was performed after the removal of the prostate. Adjuvant radiotherapy or hormonal therapy was administrated according to the pathological results. Serum PSA was detected every 1 to 2 month and urinary continence was evaluated every 3 month in the first year, and then serum PSA was detected every 2 to 3 month.
RESULTSThe mean operative time was (134±21) minutes and the median blood loss was (300±146) ml. Bladder neck reconstruction was performed in 15 cases. The drainage was removed on postoperative day 4 and the catheter was removed on day 7. Pathologic results demonstrated pT2 in 25 patients, pT3a in 28 patients, pT3b in 9 patients and pT4 in 3 patients. Positive surgical margin was presented in 15 patients. A median of 19 lymph nodes (range 11-24 nodes) were retrieved during lymphadenectomy and 11 patients had lymph nodes metastasis with a total of 19 positive nodes. Forty-three patients recovered continence after the removal of catheter. Eleven patients received adjuvant hormonal therapy and 19 patients received adjuvant radiation therapy. With the median of 20 months follow-up (range 12-30 months), 5 patients got biochemical recurrence.
CONCLUSIONSLaparoscopic radical prostatectomy with extended lymph nodes dissection for high risk prostate cancer is safe and technical feasible. It provides accurate information on tumor stage and grade. It is an important component of multimodality for the treatment of high risk prostate cancer.
Aged ; Biopsy ; Humans ; Laparoscopy ; Lymph Node Excision ; Lymph Nodes ; pathology ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Grading ; Postoperative Period ; Prostate-Specific Antigen ; blood ; Prostatectomy ; Prostatic Neoplasms ; diagnosis ; surgery
5.Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer.
Ho Won KANG ; Jin Bak YANG ; Whi An KWON ; Young Suk LEE ; Won Tae KIM ; Yong June KIM ; Seok Joong YUN ; Sang Cheol LEE ; Isaac Yi KIM ; Wun Jae KIM
Journal of Korean Medical Science 2013;28(12):1796-1800
The necessity of routine prostate biopsy prior to transurethral resection of the prostate (TURP) in elderly comorbid patients with a high prostate specific antigen (PSA) level remains controversial. We assessed the role of TURP in prostate cancer diagnosis in these individuals. A total of 197 patients underwent TURP in conjunction with prostatic needle biopsy. Pathologic reviews of specimens of TUR chips and biopsy cores were analyzed. Overall, prostate cancer (CaP) was detected in 114 patients (57.6%). Ninety-eight cancers (86%) were detected with TURP and biopsy, and seven cancers (6.1%) with only TURP. The Gleason score of a TUR-specimen was identical to that of the biopsy-core in 43.9% of cases. Variables associated with diagnostic accuracy in the TUR-specimens included the prebiopsy PSA level, prostate specific antigen density (PSAD), and the Gleason score in biopsy cores. In patients with a PSA level and a PSAD that was greater than 15.4 ng/mL and 0.69 ng/mL/g, respectively, 100% of the cancers were detected in the TUR-specimens. Our results suggest that a prostatic biopsy might be omitted prior to TURP in elderly patients with significant co-morbidity and levels for PSA of >15.4 ng/mL.
Aged
;
Aged, 80 and over
;
Area Under Curve
;
Biopsy, Needle
;
Comorbidity
;
Humans
;
Male
;
Neoplasm Grading
;
Prostate/*surgery
;
Prostate-Specific Antigen/*blood
;
Prostatic Neoplasms/*diagnosis/epidemiology/*pathology/surgery
;
ROC Curve
;
Transurethral Resection of Prostate
6.Prostate Volume has Prognostic Value Only in Pathologic T2 Radical Prostatectomy Specimens.
In Chang CHO ; Whi An KWON ; Jeong Eun KIM ; Jae Young JOUNG ; Ho Kyung SEO ; Jinsoo CHUNG ; Weon Seo PARK ; Kang Hyun LEE
Journal of Korean Medical Science 2011;26(6):807-813
The objective of this study was to evaluate the prognostic roles of the prostate volume, tumor volume, and tumor percentage as a function of the pathologic T stage in radical prostatectomy specimens. This study included 259 patients who underwent radical prostatectomy between 2005 and 2010. The mean follow-up period was 41.2 months. In all of the specimens, prostate volume (P = 0.021), the Gleason score (P = 0.035), and seminal vesicle invasion (P = 0.012) were independent predictors of biochemical recurrence (BCR). In the T2 group, multivariate analysis showed that the BCR was significantly associated with prostate specific antigen (PSA) (P = 0.028), a lower prostate volume (P = 0.004), and the Gleason score (P = 0.040). The Kaplan-Meier survival curve showed that a smaller prostate volume was significantly associated with a greater risk of BCR (< 30 vs > or = 30 mL; P = 0.010). In the T3 group, patients with seminal vesicle invasion had a significantly shorter mean BCR-free survival (P = 0.030). In this study, tumor volume and tumor percentage did not predict BCR. Notably, a lower prostate volume is an independent predictor for BCR only in the organ-confined radical prostatectomy specimens. But, prostate volume could not predict BCR in most locally advanced tumors.
Aged
;
Aged, 80 and over
;
Follow-Up Studies
;
Humans
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local/diagnosis
;
Neoplasm Staging
;
Organ Size
;
Predictive Value of Tests
;
Prostate/*pathology
;
Prostate-Specific Antigen/blood
;
Prostatectomy
;
Prostatic Neoplasms/*pathology/surgery
;
Retrospective Studies
;
Risk Factors
7.Diffusion-Weighted Magnetic Resonance Imaging for the Evaluation of Prostate Cancer: Optimal B Value at 3T.
Ji Hyun KOO ; Chan Kyo KIM ; Dongil CHOI ; Byung Kwan PARK ; Ghee Young KWON ; Bohyun KIM
Korean Journal of Radiology 2013;14(1):61-69
OBJECTIVE: To retrospectively determine the optimal b value of diffusion-weighted imaging (DWI) for predicting the presence of localized prostate cancer, and to evaluate the utility of DWI under different b values in differentiating between cancers and benign prostatic tissues. MATERIALS AND METHODS: Eighty patients with suspected prostate cancer underwent MRI including DWI at 3T, followed by radical prostatectomy. DWI was examined under different b values. Apparent diffusion coefficient (ADC) maps were generated by using b = 0, and other b values of 300, 700, 1000 or 2000 s/mm2. For predicting the presence of cancers, four different ADC maps were analyzed independently by two blinded readers. ADCs were measured in benign and malignant tissues. RESULTS: For predicting the presence of 110 prostate cancers, the sensitivity and area under the curve (AUC) for an experienced reader was significantly greater at b = 1000 (85% and 0.91) than b = 300, 700 or 2000 s/mm2 (p < 0.01). For a less-experienced reader, the AUC was significantly greater at b = 700, 1000 or 2000 than b = 300 s/mm2 (p < 0.01). Mean ADCs of the cancers in sequence from b = 300 to 2000 s/mm2 were 1.33, 1.03, 0.88 and 0.68 x 10(-3) mm2/s, which were significantly lower than those of benign tissues (p < 0.001). CONCLUSION: The optimal b value for 3T DWI for predicting the presence of prostate cancer may be 1000 s/mm2.
Aged
;
Aged, 80 and over
;
Area Under Curve
;
Biopsy
;
Diagnosis, Differential
;
Diffusion Magnetic Resonance Imaging/*methods
;
Humans
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Predictive Value of Tests
;
Prostate-Specific Antigen/blood
;
Prostatectomy
;
Prostatic Neoplasms/*diagnosis/pathology/surgery
;
Retrospective Studies
;
Sensitivity and Specificity
8.Pre-Operative Prediction of Advanced Prostatic Cancer Using Clinical Decision Support Systems: Accuracy Comparison between Support Vector Machine and Artificial Neural Network.
Sang Youn KIM ; Sung Kyoung MOON ; Dae Chul JUNG ; Sung Il HWANG ; Chang Kyu SUNG ; Jeong Yeon CHO ; Seung Hyup KIM ; Jiwon LEE ; Hak Jong LEE
Korean Journal of Radiology 2011;12(5):588-594
OBJECTIVE: The purpose of the current study was to develop support vector machine (SVM) and artificial neural network (ANN) models for the pre-operative prediction of advanced prostate cancer by using the parameters acquired from transrectal ultrasound (TRUS)-guided prostate biopsies, and to compare the accuracies between the two models. MATERIALS AND METHODS: Five hundred thirty-two consecutive patients who underwent prostate biopsies and prostatectomies for prostate cancer were divided into the training and test groups (n = 300 versus n = 232). From the data in the training group, two clinical decision support systems (CDSSs-[SVM and ANN]) were constructed with input (age, prostate specific antigen level, digital rectal examination, and five biopsy parameters) and output data (the probability for advanced prostate cancer [> pT3a]). From the data of the test group, the accuracy of output data was evaluated. The areas under the receiver operating characteristic (ROC) curve (AUC) were calculated to summarize the overall performances, and a comparison of the ROC curves was performed (p < 0.05). RESULTS: The AUC of SVM and ANN is 0.805 and 0.719, respectively (p = 0.020), in the pre-operative prediction of advanced prostate cancer. CONCLUSION: The performance of SVM is superior to ANN in the pre-operative prediction of advanced prostate cancer.
Adult
;
Aged
;
Aged, 80 and over
;
Area Under Curve
;
Biopsy, Needle
;
*Decision Support Systems, Clinical
;
Humans
;
Male
;
Middle Aged
;
*Neural Networks (Computer)
;
Prostate-Specific Antigen/blood
;
Prostatectomy
;
Prostatic Neoplasms/*diagnosis/pathology/surgery
;
ROC Curve
;
Sensitivity and Specificity
;
*Support Vector Machines
9.Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
Joseph NARICULAM ; Alex FREEMAN ; Simon BOTT ; Phillipa MUNSON ; Noriko CABLE ; Nicola BROOKMAN-AMISSAH ; Magali WILLIAMSON ; Roger S KIRBY ; John MASTERS ; Mark FENELEY
Asian Journal of Andrology 2009;11(1):109-118
A cure cannot be assured for all men with clinically localized prostate cancer undergoing radical treatment. Molecular markers would be invaluable if they could improve the prediction of occult metastatic disease. This study was carried out to investigate the expression of BCL-2, Ki-67, p53 and E-cadherin in radical prostatectomy specimens. We sought to assess their ability to predict early biochemical relapse in a specific therapeutic setting. Eighty-two patients comprising 41 case pairs were matched for pathological stage, Gleason grade and preoperative prostate-specific antigen (PSA) concentration. One patient in each pair had biochemical recurrence (defined as PSA >or= 0.2 ng mL(-1) within 2 years of surgery) and the other remained biochemically free of disease (defined as undetectable PSA at least 3 years after surgery). Immunohistochemical analysis was performed to assess marker expression on four replicate tissue microarrays constructed with benign and malignant tissue from each radical prostatectomy specimen. Ki-67, p53 and BCL-2, but not E-cadherin, were significantly upregulated in prostate adenocarcinoma compared with benign prostate tissue (P < 0.01). However, no significant differences in expression of any of the markers were observed when comparing patients who developed early biochemical relapse with patients who had no biochemical recurrence. This study showed that expression of p53, BCL-2 and Ki-67 was upregulated in clinically localized prostate cancer compared with benign prostate tissue, with no alteration in E-cadherin expression. Biomarker upregulation had no prognostic value for biochemical recurrence after radical prostatectomy, even after considering pathological stage, whole tumour Gleason grade and preoperative serum PSA level.
Adenocarcinoma
;
diagnosis
;
metabolism
;
surgery
;
Aged
;
Biomarkers, Tumor
;
metabolism
;
Cadherins
;
genetics
;
metabolism
;
Case-Control Studies
;
Gene Expression Profiling
;
Gene Expression Regulation, Neoplastic
;
Humans
;
Ki-67 Antigen
;
genetics
;
metabolism
;
Male
;
Middle Aged
;
Prognosis
;
Prostate
;
metabolism
;
pathology
;
Prostate-Specific Antigen
;
blood
;
Prostatectomy
;
Prostatic Neoplasms
;
diagnosis
;
metabolism
;
surgery
;
Proto-Oncogene Proteins c-bcl-2
;
genetics
;
metabolism
;
Risk Factors
;
Tumor Suppressor Protein p53
;
genetics
;
metabolism